Macrophage homeostasis implies proper function for its specific tissue, environment and challenge
Reprogramming imbalanced macrophage populations can lead to disease resolution
Macrophages’ function is a sum of their designation, the local environment in which they reside, and the type of situation or pathogen to which they are exposed. Reprogrammed out of their homeostatic state, macrophages contribute to the pathophysiology of multiple diseases including cancer and various inflammatory disorders.
We reset macrophages into their homeostatic state
Pipeline of reprogrammable macrophage-modulated indications
| Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
Support for EU Conditional Marketing Approval Submission |
Post EU Marketing US Phase 3 |
|
|---|---|---|---|---|---|---|---|
| Organ failure associated with Sepsis | $33B | Completed | Phase II Initiated Q1 2021 |
Completion of Phase II Q4 2022 |
|||
| ARDS associated with severe/critical COVID-19 | $1B (COVID) | Completed COVID-19 |
Phase II Completed COVID-19 |
Completion of Phase IIb Q4 2023/Q1 2023 |
|||
| Solid tumors in combination with chemotherapy, immune checkpoints | $4B | Phase Ib Q1 2022 |
|||||
Our Mission
Our mission is to establish new equilibriums that solve complex diseases.
As a clinical-stage company focused on macrophage reprogramming, we intend to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, Sepsis, COVID-19 and other indications.
Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach.
Find out more
14 Einstein St. Nes-Ziona 7403618, Israel
T +972.8.6623301 | F +972.8.6312981
info@enlivexpharm.com